(NYSE: CBT) CABOT's forecast annual revenue growth rate of 4.34% is not forecast to beat the US Specialty Chemicals industry's average forecast revenue growth rate of 6.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.91%.
CABOT's revenue in 2022 is $3,881,000,000.On average, 3 Wall Street analysts forecast CBT's revenue for 2022 to be $228,758,243,268, with the lowest CBT revenue forecast at $220,317,117,952, and the highest CBT revenue forecast at $233,553,639,472. On average, 3 Wall Street analysts forecast CBT's revenue for 2023 to be $236,630,742,744, with the lowest CBT revenue forecast at $229,967,278,600, and the highest CBT revenue forecast at $243,448,722,326.
In 2024, CBT is forecast to generate $249,646,044,208 in revenue, with the lowest revenue forecast at $244,965,095,523 and the highest revenue forecast at $257,865,836,600.